Forte Biosciences Inc (37T.F)
Frankfurt · EUR · Healthcare · Biotechnology
€65.00 (+0.00%) as of
Key statistics
- Market cap
- 1.38B
- EPS (TTM)
- -3.92
- 52-week range
- 8.70 – 68.00
- Beta
- 2.64
- Profit margin
- 0.00%
- Volume
- 100.00
About Forte Biosciences Inc
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Dallas, TX, United States
- Employees
- 23
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.